JP7440729B2 - 粘膜免疫原性を調節する方法 - Google Patents
粘膜免疫原性を調節する方法 Download PDFInfo
- Publication number
- JP7440729B2 JP7440729B2 JP2021555819A JP2021555819A JP7440729B2 JP 7440729 B2 JP7440729 B2 JP 7440729B2 JP 2021555819 A JP2021555819 A JP 2021555819A JP 2021555819 A JP2021555819 A JP 2021555819A JP 7440729 B2 JP7440729 B2 JP 7440729B2
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- medicament according
- lth
- mucosal
- influenza
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000005847 immunogenicity Effects 0.000 title description 8
- 239000000427 antigen Substances 0.000 claims description 91
- 108091007433 antigens Proteins 0.000 claims description 91
- 102000036639 antigens Human genes 0.000 claims description 91
- 208000037798 influenza B Diseases 0.000 claims description 32
- 229960005486 vaccine Drugs 0.000 claims description 27
- 230000002163 immunogen Effects 0.000 claims description 24
- 230000028993 immune response Effects 0.000 claims description 22
- 239000002955 immunomodulating agent Substances 0.000 claims description 22
- 229940121354 immunomodulator Drugs 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 17
- 230000002584 immunomodulator Effects 0.000 claims description 16
- 239000000284 extract Substances 0.000 claims description 14
- 210000004877 mucosa Anatomy 0.000 claims description 13
- 239000013566 allergen Substances 0.000 claims description 12
- 230000016379 mucosal immune response Effects 0.000 claims description 8
- 239000000428 dust Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 230000002708 enhancing effect Effects 0.000 claims description 5
- 230000024932 T cell mediated immunity Effects 0.000 claims description 3
- 230000003828 downregulation Effects 0.000 claims description 3
- 229960003971 influenza vaccine Drugs 0.000 claims description 3
- 229940062713 mite extract Drugs 0.000 claims description 3
- 210000002200 mouth mucosa Anatomy 0.000 claims description 3
- 210000002850 nasal mucosa Anatomy 0.000 claims description 3
- 239000009342 ragweed pollen Substances 0.000 claims description 3
- 230000001932 seasonal effect Effects 0.000 claims description 3
- 230000003827 upregulation Effects 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 229940127557 pharmaceutical product Drugs 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 2
- 208000037797 influenza A Diseases 0.000 claims 1
- 230000017306 interleukin-6 production Effects 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 35
- 206010022000 influenza Diseases 0.000 description 35
- 210000002966 serum Anatomy 0.000 description 33
- 238000011282 treatment Methods 0.000 description 29
- 230000003053 immunization Effects 0.000 description 25
- 244000036975 Ambrosia artemisiifolia Species 0.000 description 24
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 24
- 235000003484 annual ragweed Nutrition 0.000 description 24
- 235000006263 bur ragweed Nutrition 0.000 description 24
- 235000003488 common ragweed Nutrition 0.000 description 24
- 238000002649 immunization Methods 0.000 description 24
- 235000009736 ragweed Nutrition 0.000 description 24
- 241001465754 Metazoa Species 0.000 description 22
- 238000011740 C57BL/6 mouse Methods 0.000 description 21
- 229940099472 immunoglobulin a Drugs 0.000 description 19
- 239000002671 adjuvant Substances 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 18
- 230000002519 immonomodulatory effect Effects 0.000 description 18
- 101710154606 Hemagglutinin Proteins 0.000 description 15
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 15
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 15
- 101710176177 Protein A56 Proteins 0.000 description 15
- 239000000185 hemagglutinin Substances 0.000 description 15
- 241000700605 Viruses Species 0.000 description 13
- 229940027941 immunoglobulin g Drugs 0.000 description 13
- 238000002255 vaccination Methods 0.000 description 13
- 230000036039 immunity Effects 0.000 description 10
- 238000011278 co-treatment Methods 0.000 description 8
- 241000134304 Influenza A virus H3N2 Species 0.000 description 6
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 6
- 208000037802 influenza A (H3N2) Diseases 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000002516 postimmunization Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000007918 intramuscular administration Methods 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 108700012359 toxins Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 210000001821 langerhans cell Anatomy 0.000 description 4
- 102000007863 pattern recognition receptors Human genes 0.000 description 4
- 108010089193 pattern recognition receptors Proteins 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 108010006232 Neuraminidase Proteins 0.000 description 3
- 102000005348 Neuraminidase Human genes 0.000 description 3
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 description 3
- 208000028004 allergic respiratory disease Diseases 0.000 description 3
- 230000007123 defense Effects 0.000 description 3
- 230000002998 immunogenetic effect Effects 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 201000004335 respiratory allergy Diseases 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229940083268 Toll-like receptor (TLR) antagonist Drugs 0.000 description 2
- LTOCXIVQWDANEX-UXCYUTBZSA-M [Br-].CCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCCN)OCCCCCCCC\C=C/CCCC.CC(C)CCCC(C)CCCC(C)CCCC(C)CC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CC(C)CCCC(C)CCCC(C)CCCC(C)C Chemical compound [Br-].CCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCCN)OCCCCCCCC\C=C/CCCC.CC(C)CCCC(C)CCCC(C)CCCC(C)CC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CC(C)CCCC(C)CCCC(C)CCCC(C)C LTOCXIVQWDANEX-UXCYUTBZSA-M 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000000677 immunologic agent Substances 0.000 description 2
- 229940124541 immunological agent Drugs 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- GNENVASJJIUNER-UHFFFAOYSA-N 2,4,6-tricyclohexyloxy-1,3,5,2,4,6-trioxatriborinane Chemical compound C1CCCCC1OB1OB(OC2CCCCC2)OB(OC2CCCCC2)O1 GNENVASJJIUNER-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 241001674044 Blattodea Species 0.000 description 1
- 208000035049 Blood-Borne Infections Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010060231 Insect Proteins Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 208000022120 Jeavons syndrome Diseases 0.000 description 1
- 101710180643 Leishmanolysin Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000003441 Transfusion reaction Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000004082 barrier epithelial cell Anatomy 0.000 description 1
- 239000003659 bee venom Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003256 environmental substance Substances 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229930186900 holotoxin Natural products 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229940033324 influenza A vaccine Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 102000003835 leukotriene receptors Human genes 0.000 description 1
- 108090000146 leukotriene receptors Proteins 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229940031462 non-live vaccine Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000001243 pseudopodia Anatomy 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A61K39/36—Allergens from pollen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Otolaryngology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Description
本出願は、2019年3月20日出願の米国仮出願第62/820,966号の利益を主張し、その全体が参照により本明細書に組み込まれる。
本発明は、粘膜免疫付与の分野に関し、特に、免疫付与のために異なる粘膜部位に抗原および免疫調節剤を送達することに関する。
ワクチンの免疫原性を増強するための一般的な実施は、抗原をアジュバントなどの免疫調節剤と同時投与することを含む。組換え、精製またはスプリット抗原などの非生ワクチンのほとんどの抗原は、免疫原性が低いことが多く、免疫原性を高めるためにアジュバントに依存する。ワクチン接種のためのアジュバントは免疫調節剤に属し、それらの機構は、注射部位でのデポー形成、サイトカインおよびケモカインの誘導、常在ランゲルハンス細胞の活性化、抗原提示食細胞(APC)の動員、およびリンパ節をドレーンするための抗原提示細胞のホーミングの促進などを含むが、これらに限定されない。現在のアジュバント化ワクチンでは、アジュバントおよび抗原は予め混合され、同時に投与される。アジュバントの分子特性および反応性APCの性質に依存して、アジュバントは免疫の質および量を調節する。それにもかかわらず、別々におよび/または異なる時点で投与される免疫調節剤は、アジュバントとはみなされない(EMEA/CHMP/VWP/244894/2006)。アジュバントは、抗原に対する免疫反応を増強するように設計される。免疫調節剤は、より全身性の方法で抗原の免疫性を改変する。
本開示は、抗原および免疫調節剤を異なる粘膜部位に投与することによって、抗原の免疫原性を調節することができ、望ましい免疫応答を誘発することができるという発見に関する。したがって、本開示は、必要とする対象の粘膜部位に抗原を投与することと、前記対象の異なる解剖学的粘膜部位に免疫調節剤を投与することとを含む、粘膜免疫応答を調節するための新規方法を提供する。
図1において、マウスにFluBを舌下投与し、一部には、鼻腔内経路を介した共処置としてLTh(αK)を鼻腔内投与した(図1)。第1群では、各マウスに20μgのFluBを舌下投与した。第2群、3群および4群では、マウスに、5μgのLTh(αK)の鼻腔内投与と組み合わせて、それぞれ20μg、10μgおよび5μgのFluBを舌下経路で投与した。全ての群において、処置は、1週間間隔で、合計3回の処置を与えた。
図2では、マウスにFluA/Hong Kong/4801/2014(H3N2)様ウイルスワクチン(FluA)を舌下投与し、一部には、LTh(αK)の鼻腔内投与を共処置した(図2)。第1群では、各マウスに20μgのFluAを舌下投与した。2群、3群および4群では、マウスに、それぞれ20μg、10μgおよび5μgのFluAを、5μgのLTh(αK)と共に舌下経路で鼻腔内投与した。全ての群において、処置は、1週間、別々に、合計3回の処置で与えられた。
結論として、鼻腔内経路によるLTh(αK)の投与は、SL投与によって誘導されるFluA特異的IgGおよびIgA力価を有意に増強した。同じ結果が、Balb/cおよびC57BL/6マウスの両方で明らかになった。
マウスを、鼻腔内経路による免疫調節剤(LTh(αK))共処置を用いてまたは用いずに、舌下経路を介して、Stallergenes Greer(XPB70D3A2.5)から購入したHDM抽出物で前処理した。アレルギー反応をシミュレートするために、前処理後、マウスを気管内に1回感作し、HDM抽出物で鼻腔内に5回チャレンジした。血液試料および気管支肺胞洗浄液(BALF)を最終チャレンジの4日後に採取し、HDM特異的IgGおよびIgAをELISAによってアッセイした。
抗花粉IgGを増強することにおけるLTh(αK)の有効性を実証するために、4つの群のマウスに、鼻腔内LTh(αK)の共処置を用いてまたは用いずに3回の舌下ラウンドのブタクサ花粉抽出物(ブタクサ)を与え、続いてブタクサによる気道チャレンジをおこなった(図4)。1回目の治療では、群1は、LTh(αK)を含まない各々40μgのブタクサの舌下用量を6回受けた。群2、3および4には、5μgのLTh(αK)の鼻腔内投与と共に、それぞれ40、20および10μgの舌下ブタクサを投与した。第1の処置ラウンドの終了の9日後に開始した第2のラウンドにおいて、群1のマウスは、2週間にわたって、各々10μgの鼻腔内ブタクサを追加で6回投与した。群2、3および4は、10μgのブタクサの舌下投与および5μgのLTh(αK)の鼻腔内投与の共処置を受けた。第3ラウンドは、第2処理の11日後に開始した。これはAIT様処置であり、動物にブタクサのみを6回舌下投与した。図4Aおよび4Bに示すように、群1および2には40μgのブタクサを、群3および4には20および10μgのブタクサをそれぞれ投与した。最後のチャレンジは、3回目の処置の11日後に開始した。チャレンジにおいて、動物には、各々15μgのブタクサ鼻腔内投与をし、続いて試料を採集することを、5回反復した。Balb/cおよびC57BL/6マウスは、それぞれTh2およびTh1に対して偏った免疫学的応答を示すことが知られている。免疫学的に異なるマウスの上記の結果は、異なる免疫遺伝学的バックグラウンドを有する動物が本発明において適用され得ることを示唆する。このような結果に基づいて、Balb/cおよびC57BL/6マウスの両方における抗ブタクサIgGの量は、LTh(αK)の共処置によって上昇したと結論付けられる。さらに、アレルゲンに対するIgG増強は、LTh(αK)の処置後数週間続いた。
Claims (19)
- 粘膜免疫応答を増強することを必要とする対象の粘膜部位に投与される、抗原を含む組成物と、
前記対象の異なる解剖学的粘膜部位に投与される、免疫調節剤を含む組成物と、
を含む、粘膜免疫応答を増強するための医薬品であって、
前記抗原が舌下粘膜又は口腔粘膜に投与され、前記免疫調節剤が鼻腔内粘膜に投与され、
前記免疫調節剤がLTh(αK)である、医薬品。 - 抗原が免疫原である、請求項1に記載の医薬品。
- 抗原がワクチンである、請求項2に記載の医薬品。
- 抗原がアレルゲンである、請求項2に記載の医薬品。
- 抗原が生物学的である、請求項2に記載の医薬品。
- 前記免疫調節剤が、接触している細胞からのIL6産生を誘導しない、請求項1に記載の医薬品。
- 前記免疫応答が、抗原特異的IgGおよびそのサブクラスの産生を含む、請求項1に記載の医薬品。
- 前記免疫応答が、抗原特異的IgMおよびそのサブクラスの産生を含む、請求項1に記載の医薬品。
- 前記免疫応答が、抗原特異的IgAおよびそのサブクラスの産生を含む、請求項1に記載の医薬品。
- 前記免疫応答が、抗原特異的細胞媒介性免疫の産生を含む、請求項1に記載の医薬品。
- 前記免疫応答が治療的に有効である、請求項1に記載の医薬品。
- 前記免疫応答が免疫成分のアップレギュレーションを含む、請求項1に記載の医薬品。
- 前記免疫応答が免疫成分のダウンレギュレーションを含む、請求項1に記載の医薬品。
- 前記抗原が舌下粘膜に投与される、請求項1に記載の医薬品。
- 前記ワクチンが季節性インフルエンザワクチンである、請求項3に記載の医薬品。
- 前記季節性インフルエンザワクチンが、A型インフルエンザウイルス様ワクチン又はB型インフルエンザウイルス様ワクチンである、請求項15に記載の医薬品。
- 前記アレルゲンが、チリダニ抽出物または花粉抽出物である、請求項4に記載の医薬品。
- 前記花粉がブタクサ花粉である、請求項17に記載の医薬品。
- 前記抗原および前記免疫調節剤が連続的に投与される、請求項1に記載の医薬品。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962820966P | 2019-03-20 | 2019-03-20 | |
US62/820,966 | 2019-03-20 | ||
PCT/CN2020/079954 WO2020187255A1 (en) | 2019-03-20 | 2020-03-18 | Method of modulating mucosal immunogenicity |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022525363A JP2022525363A (ja) | 2022-05-12 |
JP7440729B2 true JP7440729B2 (ja) | 2024-02-29 |
Family
ID=72518976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021555819A Active JP7440729B2 (ja) | 2019-03-20 | 2020-03-18 | 粘膜免疫原性を調節する方法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220143177A1 (ja) |
EP (1) | EP3941520A4 (ja) |
JP (1) | JP7440729B2 (ja) |
KR (1) | KR20210141623A (ja) |
CN (1) | CN113660948A (ja) |
AU (1) | AU2020242717A1 (ja) |
BR (1) | BR112021018542A2 (ja) |
CA (1) | CA3133718A1 (ja) |
TW (1) | TWI764111B (ja) |
WO (1) | WO2020187255A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113616783A (zh) * | 2020-05-08 | 2021-11-09 | 昱厚生技股份有限公司 | 使用免疫调节剂和包含所述免疫调节剂的疫苗组合物预防或治疗冠状病毒感染的方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100172941A1 (en) | 2009-01-05 | 2010-07-08 | Michael Vajdy | Adjuvant Compositions and Methods of Use |
US20110256214A1 (en) | 2008-11-19 | 2011-10-20 | Martin Oliver German Perez | Single-time vaccines |
WO2016142448A1 (en) | 2015-03-11 | 2016-09-15 | Anallergo S.R.L. | Compositions and treatment of respiratory allergies |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2636842B1 (fr) * | 1988-09-27 | 1994-06-10 | Liege Universite Etat | Proteine de fusion d'une sequence derivee de la sous-unite b de la toxine cholerique et d'un antigene heterologue doue de proprietes immunogenes, compositions de vaccins les contenant et acides nucleiques recombinants contenant une sequence de nucleotides codant pour ladite proteine de fusion |
US5837269A (en) * | 1989-09-25 | 1998-11-17 | University Of Utah Research Foundation | Vaccine compositions and method for enhancing an immune response |
US5562910A (en) * | 1989-09-25 | 1996-10-08 | University Of Utah Research Foundation | Vaccine compositions and method for enhancing an immune response |
US5518725A (en) * | 1989-09-25 | 1996-05-21 | University Of Utah Research Foundation | Vaccine compositions and method for induction of mucosal immune response via systemic vaccination |
KR20050073865A (ko) * | 2004-01-12 | 2005-07-18 | 대한민국(전남대학교총장) | 비브리오 패혈증균 편모 구성인자 플라젤린을유효성분으로 함유하는 백신 보조제 |
TWI304838B (en) * | 2006-10-27 | 2009-01-01 | Dev Center Biotechnology | Nucleotide acid sequence and amino acid sequence of e. coli heat-labile enterotoxin, and recombinant protein |
US9700614B2 (en) * | 2012-12-17 | 2017-07-11 | Eurocine Vaccines Ab | Intranasal vaccination dosage regimen |
WO2015006384A1 (en) * | 2013-07-09 | 2015-01-15 | Texas Tech University System | Universal influenza vaccine |
WO2016138504A1 (en) * | 2015-02-26 | 2016-09-01 | Squarex, Llc | Non-specific delayed-type hypersensitivity response to treat herpes simplex virus infection |
-
2020
- 2020-03-18 US US17/440,546 patent/US20220143177A1/en active Pending
- 2020-03-18 AU AU2020242717A patent/AU2020242717A1/en active Pending
- 2020-03-18 CA CA3133718A patent/CA3133718A1/en active Pending
- 2020-03-18 JP JP2021555819A patent/JP7440729B2/ja active Active
- 2020-03-18 WO PCT/CN2020/079954 patent/WO2020187255A1/en unknown
- 2020-03-18 TW TW109109055A patent/TWI764111B/zh active
- 2020-03-18 CN CN202080021901.2A patent/CN113660948A/zh active Pending
- 2020-03-18 KR KR1020217033785A patent/KR20210141623A/ko unknown
- 2020-03-18 EP EP20773152.2A patent/EP3941520A4/en active Pending
- 2020-03-18 BR BR112021018542A patent/BR112021018542A2/pt not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110256214A1 (en) | 2008-11-19 | 2011-10-20 | Martin Oliver German Perez | Single-time vaccines |
US20100172941A1 (en) | 2009-01-05 | 2010-07-08 | Michael Vajdy | Adjuvant Compositions and Methods of Use |
WO2016142448A1 (en) | 2015-03-11 | 2016-09-15 | Anallergo S.R.L. | Compositions and treatment of respiratory allergies |
Non-Patent Citations (3)
Title |
---|
PLOS ONE,2013年,Vol.8, No.11, e80559,pp.1-6,doi:10.1371/journal.pone.0080559 |
PNAS,2008年,Vol.105, No.5,pp.1644-1649 |
Vaccine,2019年03月02日,Vol.37,pp.1994-2003 |
Also Published As
Publication number | Publication date |
---|---|
AU2020242717A1 (en) | 2021-10-28 |
JP2022525363A (ja) | 2022-05-12 |
KR20210141623A (ko) | 2021-11-23 |
EP3941520A4 (en) | 2022-08-31 |
CN113660948A (zh) | 2021-11-16 |
BR112021018542A2 (pt) | 2021-11-30 |
US20220143177A1 (en) | 2022-05-12 |
CA3133718A1 (en) | 2020-09-24 |
TW202102259A (zh) | 2021-01-16 |
EP3941520A1 (en) | 2022-01-26 |
TWI764111B (zh) | 2022-05-11 |
WO2020187255A1 (en) | 2020-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4137640B2 (ja) | 新規プロテオソーム−リポサッカリドワクチンアジュバント | |
US8182821B2 (en) | Flu vaccine admixture of mannan and flu antigen | |
Hong et al. | Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection | |
Lemere et al. | Nasal vaccination with β-amyloid peptide for the treatment of Alzheimer's disease | |
Gallorini et al. | Sublingual immunization with a subunit influenza vaccine elicits comparable systemic immune response as intramuscular immunization, but also induces local IgA and TH17 responses | |
Isaka et al. | Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant | |
Nagai et al. | Onjisaponins, from the root of Polygala tenuifolia Willdenow, as effective adjuvants for nasal influenza and diphtheria–pertussis–tetanus vaccines | |
AU2002245636A1 (en) | A novel proteosome-liposaccharide vaccine adjuvant | |
Jones et al. | Protollin™: a novel adjuvant for intranasal vaccines | |
JP7440729B2 (ja) | 粘膜免疫原性を調節する方法 | |
EP2359850A1 (en) | Single-time vaccines | |
Berstad et al. | Inactivated meningococci and pertussis bacteria are immunogenic and act as mucosal adjuvants for a nasal inactivated influenza virus vaccine | |
Smaldini et al. | Oral delivery of Brucella spp. recombinant protein U-Omp16 abrogates the IgE-mediated milk allergy | |
WO2008037033A1 (en) | Flu vaccine admixture of mannan and flu antigen | |
Gursel et al. | Use of CpG oligonucleotides as mucosal adjuvants | |
KR101719913B1 (ko) | 상심자 추출물을 유효성분으로 함유한 경구용 면역 보조제 | |
EP1622641A2 (en) | Vaccinating against infectious diseases using proteosomes | |
Tsai et al. | Mucosal vaccine delivery | |
Plante et al. | Nasal proteosome subunit flu vaccine elicits enhanced mucosal IgA, serum HAI and protection comparable to conventional injectable flu vaccine | |
Liu et al. | CpG oligodeoxynucleotide is an effective adjuvant for transcutaneous immunization | |
Saluja | Novel perspectives for influenza vaccine formulation and administration | |
Gursel et al. | Use of CpG Oligonucleotides as Mucosal Adjuvants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211029 Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20211012 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211029 |
|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20211012 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221129 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230222 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230523 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230818 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231023 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231124 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240109 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240124 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7440729 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |